Advertisement

Picture Berlin Partner Hotspot for Startups 650x80px
Organisation › Details

Algeta ASA (Oslo Stock Exchange: ALGETA)

Algeta is a company focused on developing novel targeted therapies for patients with cancer based on its alpha-pharmaceutical platform. Algeta's lead product Alpharadin (radium-223 chloride) is a first-in-class, highly targeted alpha-pharmaceutical under clinical evaluation to improve survival in patients with bone metastases from advanced cancer. Its localized action helps preserve the surrounding healthy tissue thereby limiting side-effects. Alpharadin is being developed under a development and commercialization agreement with Bayer Pharma AG (formerly Bayer Schering Pharma AG). In June 2011, a global phase III clinical trial (ALSYMPCA) of Alpharadin to treat bone metastases in patients with castration-resistant prostate cancer (CRPC) was stopped early after meeting its primary endpoint of significantly improving overall survival. Alpharadin is also under investigation in phase II clinical trials as a potential new treatment for bone metastases in endocrine-refractory breast cancer patients, and in a phase I/IIa trial in combination with docetaxel chemotherapy in for bone metastases CRPC patients. The development of bone metastases represents a serious development for cancer patients as they are associated with a dramatic decline in patient health and quality of life, ultimately leading to death. Bone metastases represent a major unmet medical need, occurring frequently in certain late-stage cancers, e.g. prostate (in up to 90% patients), breast (up to 60 %) and lung (up to 40%). Algeta is also exploring the potential of Targeted Thorium Conjugates (TTCs), which are based on conjugating the alpha-emitter thorium-227 to targeting molecules, as a basis of a future pipeline of tumor-targeting alpha-pharmaceutical candidates. The Company is headquartered in Oslo, Norway, and is listed on the Oslo Stock Exchange (Ticker: ALGETA). *

 

Period Start 1997-01-01 established_pre
  Group Bayer (Group)
  Predecessor Anticancer Therapeutic Innovations AS
Products Industry RADIOPHARMACEUTICAL (RPT)
  Industry 2 cancer drug
Persons Person Kay, Andrew (NuCana 202012– Board Chairman also at Boards of NeRRe Tx + Blueberry Tx former CEO of Algeta)
  Person 2 Soug, Øystein (Targovax 201809 CEO before CFO sind 201506 before Algeta + Orkla Group)
     
Region Region Oslo
  Country Norway
  Street 172A Kjelsasveien
P.O. Box 54 Kjelsas
  City 0411 Oslo
  Tel +47-23-007990
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
  Currency NOK
  Annual sales 635,000,000 (revenue, consolidated (2013) 2013-12-31)
  Profit -219,500,000 (2013-12-31)
  Cash 1,367,000,000 (2013-12-31)
     
    * Document for �About Section�: 
     
   
Record changed: 2020-12-22

Advertisement

Picture [iito] Made Without Love 650x80px

More documents for Bayer (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Demy-Colton BioFuture 2021 NYC D Meet Top Investors 650x300px




» top